The compounds that have been most extensively studied in the chemotherapy of human immunodeficiency virus (HIV) infections are the 2',3'-dideoxynucleoside (ddN) analogues 3'-azido-3'-deoxythymidine (zidovudine; AZT), dideoxycytidine (ddC), and dideoxyinosine (ddl) (1) . These compounds interfere with the virus-associated reverse transcriptase (RT) . To this end, they need to be phosphorylated intracellularly by host enzymes to their 5'-triphosphate (ddNTP), which then interact as DNA chain terminators in the RT reaction (2) . Other, nonnucleoside inhibitors ofthe HIV-1 RT have been recently identified (3) (4) (5) that directly interact with the enzyme at a specific target site, provisionally designated as the TIBO {tetrahydroimidazo [4,5,1- In addition to the RT, several other stages in the HIV replicative cycle, starting from the virion binding to the cells to the ultimate release (budding) of the virus particles from the cells, have been envisaged as targets for therapeutic intervention (7) (8) (9) (10) . One such target is the HIV protease, and several HIV-1 protease inhibitors have been designed that appear to inhibit the enzyme, and consequently virus replication, with high specificity (11) (12) (13) (14) (15) (16) . The viral protease is essential for proper assembly of mature, fully infectious HIV particles. The uncoating process has also been proposed as a possible target for anti-HIV agents (17) . This suggestion was based on the possible similarity in tertiary structure between the HIV capsid protein(s) and the capsid protein of picornaviruses, which have indeed proved sensitive to uncoating inhibitors (18) .
Therapeutic strategies targeted at the HIV uncoating process would be worth pursuing, as they should block the release of the functional RNA inside the cells and thus interrupt the HIV replicative cycle before it proceeds to the RT step. To date, no compounds have been shown to act at the uncoating of HIV or retroviruses in general. In a review article (10) , it was mentioned that the aromatic polycyclic diones hypericin and pseudohypericin may inhibit the process of uncoating. However, in the original publications (19, 20) , these compounds were reported to directly inactivate retrovirions as well as to inhibit their assembly. Here we report on a newly discovered class of potent and selective HIV inhibitors, which seem to be targeted at a virus uncoating-associated process.
MATERIALS AND METHODS
Compounds. Cyclam (JM1498) was supplied by Aldrich. The isolation of the free base of JM1657 as an impurity in the large scale preparation of cyclam has been described (21) . JM2762 and JM2763 were synthesized by published procedures (22) . JM2849 and JM2936 were prepared at Johnson Matthey. The cyclam JM1498 was tested as the free base. Other compounds were tested as the octahydrochlorides.
Viruses, Cells, Antiviral Activity Assays, and Cytotoxicity Assays. Anti-HIV activity and cytotoxicity measurements in MT-4 cells (origin of the MT-4 cells is described in ref. 23) were based on viability of cells that had been infected or not infected with HIV and then exposed to various concentrations of the test compounds. After the MT-4 cells were allowed to proliferate for 5 days, the number of viable cells was quantified by a tetrazolium-based colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method in 96-well microtrays (24 After addition of virus and MT-4 cells, the trays were incubated for 5 days at 370C. Cell viability was determined by the MTT procedure (24) and is expressed in OD units. To assess whether the drug combination resulted in a synergistic, additive, or antagonistic effect, a three-dimensional method of analysis [MacSynergy (35) ] was used (R.P., unpublished data). Theoretical additive interactions were calculated from the dose-response curves of the individual drugs. The resulting dose-response surface was then compared with the actual dose-response surface. For an additive interaction the actual dose-response surface would coincide with the theoretical one, but any peaks above or below this surface would be indicative of synergy or antagonism, respectively. Significance was assessed by 95% confidence intervals around the experimentally obtained dose-response surface.
RESULTS AND DISCUSSION
A variety of macrocyclic polyamines, with the cyclam 1,4,8,11-tetraazacyclotetradecane (JM1498) used as the prototype, were synthesized and analyzed for anti-HIV activity. The monocyclam had slight activity against HIV-1 and HIV-2. Compounds in which two cyclam units were linked in various ways (bicyclams), in particular JM1657 and JM2763, were found to be active against HIV-1 and HIV-2 at a concentration as low as 0.14 kLM (Table 1) , with a selectivity index of >5000 ( Table 2 ). The anti-HIV activity of JM1657 and JM2763 was observed with several strains of both HIV-1 and HIV-2 in different cell types, including PBLs ( Table 2) . Irrespective of the method used to assess anti-HIV activityi.e., inhibition of viral cytopathicity, antigen expression, p24 production, plaque, or focus formation-the bicyclams invariably inhibited HIV-1 and HIV-2 within the concentration range of 0.14-1.4 ,uM. Also, AZT-resistant HIV-1 strains were as sensitive as AZT-sensitive HIV-1 strains to JM2763 ( Table 2 ). The sensitivity of the clinical HIV-1 isolate A018A to JM2763 varied considerably from one assay to another [IC50, 2.5 to >373 ,AM ( When JM2763 was assayed against HIV-1(IIIB) in combination with AZT, the compounds appeared to act in an additive fashion at the concentrations used ( Fig. 1 ) (confidence limits, 95%). The method used for analysis of drug combinations appeared suitable to clearly distinguish additive combinations (JM2763 plus AZT) from synergistic combinations (i.e., TIBO + AZT, ddI + ribavirin) and antagonistic combinations (i.e., AZT plus ribavirin) (R.P., unpublished data).
In attempts to resolve the mechanism of action of the bicyclams, we found that, unlike dextran sulfate, pentosan polysulfate, and the polyoxometalate K13[Ce(SiWj1O39)2] When tested under the same conditions, dextran sulfate, pentosan polysulfate, and JM1590 inhibited syncytium formation by 50% at a concentration of 10-15 ,g/ml (see also refs. 37 and 38) . Thus, at the concentrations that are effective in inhibiting viral cytopathicity, JM1657 and JM2763 fail to inhibit the formation of giant cells in a direct syncytium formation assay. In this respect, JM1657 and JM2763 clearly differ from those compounds [i.e., mannose-specific plant lectins (39) , succinylated concanavalin A (40), and succinylated human serum albumins (41) ] that inhibit the formation of giant cells (in a direct syncytium formation assay) at concentrations similar to those required to inhibit viral cytopathicity. JM2763 was also examined for its ability to interact directly with the cellular CD4 receptor for HIV and the viral envelope glycoprotein gp120. Under conditions in which aurintricarboxylic acid (42) effectively interacted with the CD4 receptor (as monitored by interference with the binding of OKT4A/ Leu3a monoclonal antibody), and under conditions in which dextran sulfate (43) effectively blocked the binding of antigp120 monoclonal antibody to persistently HIV-1-infected HUT-78 cells, JM2763 (at 0.124 mM) had no effect on either the CD4 cell receptor or viral gpl20 glycoprotein.
Also, the RT could be excluded as a target for the bicyclams. JM2763 did not inhibit the activity of HIV-1 recombinant RT, HIV-2 recombinant RT, HIV-1(IIIB) virionderived RT, HIV-2(ROD) virion-derived RT, whether directed by poly(A)-oligo(dT) or poly(C)-oligo(dG) as template-primer, at concentrations up to 5 mM. Under the same test conditions, the polyoxometalate JM1590 effected a 50% reduction in HIV-1 RT activity [with poly(A)-oligo(dT) as template-primer] at 3.1 nM, and the TIBO derivative (14)] reduced p24 antigen production by -85%.
Preincubation of HIV-1(IIIB) with JM1657 or JM2763 at concentrations up to 100 ,g/ml (144 and 124 ,uM, respectively) did not cause a decrease in virus infectivity (106 cell culture ID50/ml), which indicates that the bicyclams, unlike hypericin and pseudohypericin (20) , do not directly inactivate the virus. In fact, when hypericin was evaluated for its inhibitory effects on the cytopathicity of HIV-1 or HIV-2 in MT-4 cells, no activity was observed at subtoxic concentrations (50%o cytotoxic concentration, 5 ,uM).
To pinpoint at which stage the bicyclams actually interact with the HIV replicative cycle, a time-of-addition experiment was carried out (Fig. 2) . The cells were infected at high virus multiplicity to ensure that the virus replicative steps would be synchronized in the whole cell population, and the compounds were added 1, 2, 3,. . . 22, 23, or 24 hr after infection. Depending on the stage at which they interact and the need for intracellular metabolism, addition of the compounds could be delayed for n hr without loss of activity. Dextran sulfate, which acts at the virus adsorption step (44, 45) , must be added together with the virus (n = 0) to be active. For AZT and ddI, which, following their intracellular phosphorylation, act at the RT step (2), addition to the cells could be delayed until -5 hr (n = 5) after infection, and for the TIBO derivatives (R82150, R82913), which do not need intracellular transformations before they can interact with their target enzyme (HIV-1 RT) (4, 6) , the addition could be delayed by another 2 hr (n = 7). The protease inhibitor Ro31-8959 [compound XVII (14) ], which interacts with a late event in the virus cycle (assembly of mature virions) (11) (12) (13) (14) (15) (16) was still effective if added as late as 21 hr after infection (n = 21). From the time-of-addition experiment, it appeared that the bicyclams JM1657 and JM2763 (n = 1 or 2) had to interact with a process following virus adsorption but preceding reverse transcription, which means virus-cell fusion and/or uncoating. As mentioned above, the bicyclams are not inhibitory in the direct syncytium formation assay at concentrations that are inhibitory to HIV replication. This makes them clearly different from previously reported virus-cell fusion inhibitors (39) (40) (41) . To obtain further evidence for the inhibitory effect of JM2763 on HIV uncoating (or fusion), experiments were designed whereby the viral RNA harvested from cells that had just been infected was monitored for its sensitivity to degradation by RNase. It was reasoned that if uncoating (fusion) would be hampered, the viral capsid (or envelope) proteins would remain associated with the viral RNA genome and thus the RNA should be protected against RNase attack. When MT-4 cells were exposed to radiolabeled HIV-1(IIIB) particles (45) 
